PTCT Ptc Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTCT

Price (delayed)

$44.12

Market cap

$3.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.9

Enterprise value

$3.81B

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
Ptc Therapeutics's revenue has increased by 35% YoY and by 10% from the previous quarter
PTCT's gross profit is up by 35% YoY and by 10% QoQ
Ptc Therapeutics's equity has decreased by 32% QoQ
The company's debt rose by 32% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ptcbio.com
Peers: SRPT VRTX FATE RNA

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
74.19M
Market cap
$3.27B
Enterprise value
$3.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.94
Earnings
Revenue
$770.45M
EBIT
-$505.9M
EBITDA
-$349.63M
Free cash flow
-$321.72M
Per share
EPS
-$7.9
Free cash flow per share
-$4.36
Book value per share
-$6.2
Revenue per share
$10.45
TBVPS
$11.4
Balance sheet
Total assets
$1.61B
Total liabilities
$2.07B
Debt
$701.17M
Equity
-$457.56M
Working capital
$171.76M
Liquidity
Debt to equity
-1.53
Current ratio
1.39
Quick ratio
1.11
Net debt/EBITDA
-1.53
Margins
EBITDA margin
-45.4%
Gross margin
93.7%
Net margin
-74.1%
Operating margin
-63.6%
Efficiency
Return on assets
-34.1%
Return on equity
N/A
Return on invested capital
-60.6%
Return on capital employed
-43.3%
Return on sales
-65.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
1.43%
1 week
3.42%
1 month
-19.74%
1 year
62.38%
YTD
15.59%
QTD
-8.92%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$770.45M
Gross profit
$721.76M
Operating income
-$490.31M
Net income
-$571.25M
Gross margin
93.7%
Net margin
-74.1%
Ptc Therapeutics's revenue has increased by 35% YoY and by 10% from the previous quarter
PTCT's gross profit is up by 35% YoY and by 10% QoQ
The company's operating income fell by 31% YoY and by 3.6% QoQ
The company's net margin rose by 19% YoY and by 7% QoQ

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.94
The EPS is down by 7% year-on-year
Ptc Therapeutics's equity has decreased by 32% QoQ
The price to sales (P/S) is 40% lower than the 5-year quarterly average of 7.0 and 8% lower than the last 4 quarters average of 4.6
Ptc Therapeutics's revenue has increased by 35% YoY and by 10% from the previous quarter

Efficiency

How efficient is Ptc Therapeutics business performance
The ROIC has plunged by 52% YoY
Ptc Therapeutics's ROA has decreased by 27% YoY and by 4.9% from the previous quarter
The ROS is up by 11% year-on-year and by 8% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 22% less than the total liabilities
The quick ratio has declined by 27% year-on-year and by 20% since the previous quarter
Ptc Therapeutics's current ratio has decreased by 19% QoQ and by 14% YoY
PTCT's debt to equity has surged by 74% year-on-year and by 25% since the previous quarter
Ptc Therapeutics's equity has decreased by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.